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Abbreviations: TNC, total number of cases; TND, total 
number of deaths, TA, total number of active cases; TS, total number 
of critical serious cases; TE, total number of tests
Introduction
The corona virus, known since the 1960ies are zootonic strains of 
RMA genome viruses, all resulting from an evolution of other animals 
and that, following some mutations, recombinations and adaptations, 
may be transmitted to humans. This virus strain may cause infections 
in humans, usually respiratory, but with a symptomatology that 
may vary form asymptomatic cases to pseudo flu states, more or 
less serious. On limit situations, the clinical framework may evolve 
to an acute respiratory insufficiency, pneumonia and even be life 
threatening. 
COVID–19 was the name given by WHO to the disease caused 
by the new SARS–Cov2 coronavirus. The transmission more usually 
occurs through droplets produced in the respiratory tract, that may 
reach the mouth, eyes, nose or hands of bystanders. Current evidence 
does not exclude transmission through hands and clothes having been 
in contact with droplets on various surfaces, that previously touched 
the face in proximity of respiratory or ocular mucous membranes.1
Over the last 60 years, seven coronaviruses varieties were 
identified, four of them with relatively lighter effects similar to 
common colds: the first in 1960, the HCov–229E, followed by 
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Abstract
Introduction
It is essential to understand, on a large geographical scale, the dimension of the COVID–19 
pandemic by identifying the most affected countries, knowing that all the world is suffering 
an unusual disruption regarding several health impacts, but also heavy economic, financial 
and social effects. A key role is reserved to Data Science to understand the present and to 
deepen a prospective analysis at COVID–19 day after.
Objective
The main objective of the present study is to describe the COVID–19 prevalence in EU and 
five other OECD countries using five epidemiological variables. Secondly their association 
with non–pharmaceutical measures taken in some countries to control and attenuate the 
evolution of the epidemic was analyzed.
Methods
The COVID–19 study covers twenty–six EU countries and additionally Switzerland, 
Norway, Turkey, Israel and United Kingdom. Five epidemiologic variables were analyzed 
by 100.000 inhabitants at the beginning of May 2020: total number of cases, total number 
of deaths, total number of active cases, total number of critical or serious cases and total 
number of tests. Also, eight non–pharmaceutical measures were selected for association 
purposes. A multivariate statistical exploratory approach with principal components, 
hierarchical and non–hierarchical (k–means) cluster analyses was applied.
Results
A COVID–19 prevalence typology of four country clusters was identified regarding EU 
countries and five OECD countries on early May. In the two clusters, with a total of ten 
countries where the pandemic seemed to evolve more seriously, different patterns regarding 
the number of tests are observed. Two other clusters, with 12 and 9 countries, show an 
intermediate or low prevalence but differences in testing patterns.
For EU countries of both clusters more affected, COVID–19 containment strategies were 
studied considering three modalities of implementation timing for eight non–pharmaceutical 
measures. The three different behaviors mirrored the clusters findings. Countries previously 
classified into cluster 1 appear together again, as do countries belonging to cluster 2. In spite 
of a common behavior for some measures, generally countries of cluster 2 implemented 
other interventions later in time. Sweden is a “special case”, taking just a few of these 
measures, most of them later than other countries.
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HCov–OC43 and HCov–NL63 in 2004 and HCov–HKU1 on the 
following year. The first more recent aggressive coronavirus, SARS–
Cov, appears between 2002 and 2003, causing an acute respiratory 
syndrome. In 2012 occurs the second, MERS–Cov, responsible for 
the Middle East Respiratory Syndrome, and, at the end of 2019, the 
present SARS–Cov 2 outbreak became a real pandemic. 
The most common symptoms associated with COVID–19 are high 
fever, cough and difficulty breathing. Additionally, new manifestations 
that affect different organs or systems are increasingly being 
described, such as myalgia, headache, odynophagia, conjunctivitis, 
nasal congestion, anosmia and dysgeusia, heart problems, kidney 
failure and gastrointestinal problems. However, about 80% of 
diagnosed patients are asymptomatic or have mild symptoms, 15% 
are more severely affected and will need oxygen and about 5% have a 
critical clinical condition, requiring hospitalization in intensive care. 
The severity of the disease is enhanced by comorbidities resulting 
from old age or chronic diseases such as cardiovascular or pulmonary 
diseases, diabetes, changes in the immune response and overweight 
or obesity, among others,2 as well as by asymptomatic patients, who 
seem to transmit the disease at a lesser level, or presintomatics, who 
stand in the period of time when the virus is totally asymptomatic, but 
who are transmitters of the disease. The average incubation period in 
quarantined patients was estimated at 5.1 days. The WHO gives us a 
window of 2 to 14 days, but several studies state that in 1% of cases, 
symptoms will only develop after 14 days of active monitoring or 
quarantine.3
Currently, there is a broad scientific consensus that COVID–19’s 
severe clinical conditions are associated with intravascular coagulation 
problems that can precipitate the patient’s death.4
In the context of the evolutionary development of vertebrates, 
about 430 million years ago, a mechanism capable of stopping 
haemorrhages through the acquired blood clotting ability appeared. 
However, at older ages or in the context of the human organism’s 
response to certain pathologies, there is sometimes an exaggerated 
coagulant reaction that explains that thrombosis is a more frequent 
cause of death than haemorrhage itself.5  
COVID–19 is a viral disease associated with a systemic 
inflammatory response, acute interstitial pneumonia and mechanisms 
of activation of coagulation, both at the pulmonary level and in 
the other organs. In fact, the targets of this virus are the glandular 
epithelia of the respiratory and digestive tracts, although the virus also 
has tropism for vascular endotheliums.6–8 
We can identify three phases of COVID–19:
1– Infection phase, the step of the viral response;
2– Pulmonary phase, a step of trying to balance the viral response 
and the inflammatory response of the organism where the thrombotic 
process begins;
3– Phase of hyper–inflammation, where the exaggerated response of 
the organism worsens the clinical framework. 
During these phases, the disease tends to worsen according to 
certain easily measurable analytical parameters. Among them, the D–
Dimer indicates the existence of abnormal levels of fibrin, that is, the 
formation of blood clots in the arteries or veins, which are likely to 
generate a severe clinical framework or even the patient’s death. These 
facts had already been reported on January 31 by pathologists from 
hospitals in Wuhan and later confirmed in Italian, Dutch and North 
American patients. Therefore, the detection of thrombus formation is 
one of the main markers that reveals a poor COVID–19 prognosis.9 
However, in reality, Science does not yet fully understand the 
mechanisms that explain the lethality of this virus and how exactly 
it affects different organs and systems. Is pneumonia prevalent? Or 
blood clots? Or is it essentially a massive reaction from the immune 
system? In fact, the virus multiplies inside the cells and in the most 
severe cases the human body responds with a massive discharge of 
inflammatory cytokines released through the overactivation of white 
blood cells, causing high fever, blood clots, hypotension, lack of 
oxygen, acidification blood and pulmonary edema. In these situations, 
the clinical picture may even progress to the point where the white 
blood cells attack indiscriminately, reaching the healthy tissue itself 
and causing pulmonary, cardiac, hepatic, intestinal, renal and even 
genital insufficiency. This in turn can substantiate the Multiple Organ 
Dysfunction Syndrome (MODS), which, if not controlled in a timely 
manner, will facilitate the deposit of proteins and dead cells in the 
lung tissue, preventing oxygenation and hindering inexorably life.10,11
Currently, there is no proven effective treatment for COVID–19. 
In the early or mild stages of the disease, symptomatic treatment 
with anti–inflammatories and antipyretics has been used. In the most 
advanced stages, depending on the patient’s general clinical condition, 
antimalarial, antiviral treatments of various types are used, as well 
as immunological modulators, whether corticosteroids, monoclonal 
antibodies or blood plasma transfusions of recovered patients. In 
patients hospitalized with COVID–19 in intensive care, antithrombotic 
strategies are part of the action protocol, with low molecular weight 
heparins with prophylactic or intermediate dosages, considered 
indicated when the values of the D–Dimer parameter are higher than 
normal values. Therapeutic anticoagulation is reserved for cases in 
which a local or systemic thrombotic pathology is diagnosed.12–14 
Presently, very wide clinical trial protocols are being done 
worldwide, from which more concrete results are expected.
Concomitantly, we are witnessing a global race in the search for 
an effective vaccine for COVID–19, through well–differentiated 
research clues. The complexity of this process and the high level of 
safety required do not foresee a short–term availability of this active 
substance. 
The COVID–19 outbreak was officially declared a pandemic 
by WHO on March 11, 2020, hitting Europe more strongly after 
February/March 2020. Over this period many European countries 
implemented non–pharmaceutical interventions (NPIs) to try and 
contain the effects of the epidemic. The first cycle of confinement 
extends roughly until the beginning of May (May 2/4), after which 
less strict measures begun to be taken gradually.15
The main aim of this paper is to study the COVID–19 prevalence 
in EU countries and European OECD countries, over the period 
February 25–May 4 2020, corresponding to the first cycle of 
confinement identifying higher prevalence clusters and associating 
them with non–pharmaceutical measures typologies. 
Future studies will further analyse the following cycles, as less 
restrictive measures will be undertaken regarding the mobility of 
populations, economic activity and more advanced deconfinement 
phases.
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Given the framework of a high contamination outbreak with great 
uncertainty regarding the length of virus survival, the viral load and 
the mutation rate, as well as the most reliable data available, five 
variables were selected to characterize the epidemiological impact of 
the virus on populations and health systems: Total number of cases 
(TNC); Total number of deaths (TND); Total number of active cases 
(TA); Total number of critical serious cases (TS) and Total number 
of tests (TE). To assure the comparability between countries, these 
indicators were analysis per 100.000 inhabitants (given the 2018 
populations country censuses).
Possible associations were analysed between these epidemiological 
indicators and a set of eight non–pharmaceutical measures taken by 
European governments to slow the pandemic evolution: Stay–at–home 
(Orders–enforced, Recommendations for the general population, 
Recommendations for risk groups); Closure of educational institutions 
(Secondary schools/higher education, Primary schools, Daycare), 
Closure of public places, Mass gathering cancellations.15
Methods 
Data
This study includes 32 countries – EU countries and five OECD 
surrounding countries (Israel, Norway, United Kingdom, Switzerland 
and Turkey). 
Epidemiological data drawn from Worldometer referring to May 
4th,16 and the European Centre for Disease Prevention and Control, 
referring to May 2nd include the following five variables: Total number 
of cases, Total number of deaths (both until 02 May 2020), Total 
number of active cases, Total number of critical serious cases and 
Total number of tests (all until 04 May 2020). Indicators per 100.000 
inhabitants were calculated, considering 2018 population data from 
the World Bank, through ECDC.17
Information on non–pharmaceutical interventions to prevent a 
large upsurge and their implementation dates were taken from ECDC’s 
Rapid Risk Assessment and take into account the following eight 
measures: Stay–at–home (Orders–enforced, Recommendations for 
the general population, Recommendations for risk groups); Closure 
of educational institutions (Secondary schools/higher education, 
Primary schools, Daycare), Closure of public places, Mass gathering 
cancellations.15 This information was considered for the following 
nine countries, with higher COVID–19 prevalence: Belgium, France, 
Ireland, Italy, Netherlands, Portugal, Spain, Sweden and United–
Kingdom. Each non–pharmaceutical intervention was recoded into 3 
categories: measure not taken; measure taken before March 17, 2020; 
measure taken on March 17, 2020 or after.
Statistical analysis 
Firstly, a univariate statistical analysis of the epidemiologic 
variables was performed using location and dispersion statistics, 
quantiles and a Box–plot analysis to visualize the empirical distribution 
of each variable and identify lowest and highest behaviors, namely 
possible outliers. 
Secondly, a bivariate statistical analysis interpreting the Pearson 
correlation matrix was undertaken to assess the statistical linear 
association between any pair of the epidemiologic variables. 
Then, a Principal Component Analysis (PCA) was executed to 
identify a small number of latent variables (principal components), 
linear combinations of the initial centered variables, likely to explain 
a significant part of the total inertia of the dataset. 
The two retained factors that better described the linear correlation 
coefficient between each of the principal components and the variables 
being studied were selected by examining the factor loading matrix. 
Indeed, for each variable, the sum of squares of correlations with 
the two principal components gives us the part of variance of such 
variables explained by two first factors. 
The “reducted structure” obtained from the first two factors was 
then used to construct the country’s typology using the squared 
Euclidean distance matrix between any pair of countries. An 
ascending hierarchical classification using the Ward method for 
class aggregation was applied. This procedure gives us a highlight 
concerning the number of classes to be considered. Then the cluster 
analysis by k–means methods was used to obtain a sample partition 
into four classes, which allowed the identification of sub clusters of 
countries with a specific epidemiologic profile at the beginning of 
May 2020. 
Considering the level of statistical asymmetry identified for some 
of the variables under study, a statistical rank analysis was used to 
obtain a global overview of the countries’ rank within each cluster. 
Finally, the association between the countries of the main two 
identified countries clusters and the set of non–pharmaceutical 
interventions taken by decision–makers along the first period of 
COVID–19 pandemic was analyzed (measure not taken; measure 
taken before March 17, 2020; measure taken on March 17, 2020 or 
after).
Results 
Univariate analysis
A univariate statistical analysis of the five quantitative 
epidemiological variables was performed and can be found in 
Table 1. This Table shows clearly that even excluding the smallest 
and the highest observations (respectively, below first quartile 
and above third quartile), almost all the variables have a very high 
relative dispersion evaluated here by the Quartile based variance 
coefficient (QCV=Interquartile Range/Median). The mortality 
prevalence especially is very heterogeneous across the countries 
under study, where QCV is approximately 5.5. Complementary, the 
Box–plot analysis (Figure 1) provides a visualization of the empirical 
distribution of each variable. 
With regard to the total number of COVID–19 cases, Lithuania, 
Lithuania, Croatia, Poland, Greece, Bulgaria, Hungary, Romania and 
Slovakia, registered less than 57.8 cases per 100,000 inhabitants (first 
quartile), while Switzerland, Portugal, Ireland, Italy, Spain, Belgium 
and the United Kingdom reported, until May 2, more than 238.7 cases 
per 100,000 inhabitants. Luxembourg appears as an outlier with 625.6 
COVID–19 cases per 100,000 inhabitants. This extreme situation may 
be related to the exceptionally high number of tests carried out to date 
in a country with a relatively small population.
With regard to the number of COVID–19 deaths, Latvia, Cyprus, 
Lithuania, Malta, Greece, Bulgaria and Slovenia recorded less than 
1.8 deaths per 100,000 inhabitants in contrast to Ireland, Italy, Spain, 
Belgium, United Kingdom, Netherlands, France and Sweden with 
more than 21.5 deaths per 100,000 inhabitants. The distribution of 
this variable is particularly asymmetric, with Spain and Belgium 
appearing as outlier countries with 53.1 and 67.4 deaths per 100,000 
inhabitants, respectively.
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Table 1 Univariate analysis of the epidemiologic variables for 32 countries 
N Mean SD Coef. Of Variation 1.º Quartile Median 3.º Quartile IQR IQR/ Med
Cases  
Per 100 000  
(until May 2, 2020)
31 177.2 151.2 0.9 57.8 147.3 238.7 180.9 1.28
Death Per 100 000 31 13.6 17.8 1.3 1.8 4.0 21.5 19.7 5.53
Active cases per 100 
000 (until May 4, 2020) 31 82.0 76.1 0.9 25.3 42.7 144.9 119.6 2.82
Serious critical per 100 
000 (until May 4, 2020) 31 1.70 1.60 0.9 0.50 1.10 2.4 1.9 1.73
Tests per 100 000 
(until May 4, 2020) 31 3024 1863.2 0.6 1382.5 3113 4200.8 2018 0.65
Figure 1 Boxplots for epidemiologic variables.
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In the sub universe of reported cases, the number of active cases per 
100,000 inhabitants will tend to overestimate the real value. In fact, 
at the time of this study, some countries had not given priority to the 
counting of recovered patients, in view of the high pressure healthcare 
professionals faced to attend the most serious cases and respond to 
the urgent need to increase the number of tests in pandemic focal 
areas. Austria, Malta, Croatia, Poland, Greece, Bulgaria, Hungary 
and Slovakia registered less than 25.3 active cases per 100,000 
inhabitants. A particular highlight should be given to the effective 
response given in Austria. In contrast, Portugal, Ireland, Italy, Spain, 
Belgium, the United Kingdom, the Netherlands and Sweden showed 
more than 144.9 active cases per 100,000 inhabitants. In some of these 
countries the explanation for these values may lie in the higher and 
growing number of new cases that appeared over the reference period, 
immediately before our study. 
As for the total number of COVID–19 patients in critical condition, 
it is a particularly sensitive variable, directly related with the logistical 
capacity of health infrastructures to respond in due time, offering 
intensive treatments to patients in life threatening conditions. Latvia, 
Estonia, Malta, Croatia, Poland, Greece and Slovakia registered less 
than 0.5 critical cases per 100,000 inhabitants. This means that, in 
these countries, at the time of the study, there may have been no 
effective pressure on treatment and intensive care services, largely 
due to the relatively small number of registered COVID–19 cases.
However, in Italy, Spain, Belgium, the Netherlands, France 
and Sweden, there were more than 2.4 critical cases per 100,000 
inhabitants, testing the installed capacity of hospital services despite 
being inserted in some of the largest economies in Europe. Finally, 
the Netherlands, Sweden, Croatia, Poland, Greece, Bulgaria, Hungary 
and Romania had less than 1382.5 per 100,000 inhabitants. In the case 
of Holland and Sweden, the less strict option in terms of mitigation 
taken contrasts with the high number of COVID–19 cases registered 
at the time of our study. Inversely, Portugal, Denmark, Estonia, Israel, 
Cyprus, Lithuania and Malta have conducted more than 4200.8 tests 
on May 2 per 100,000 inhabitants.
Bivariate and multivariate analysis
In a second step a bivariate analysis of the data set was applied, 
previously excluding Iceland and Luxembourg, both outliers regarding 
the number of tests per 100,000 inhabitants. 
The correlation matrix (Table 2) reveals a strong positive 
correlation between any pair of four epidemiologic variables – cases, 
deaths, active cases and serious critical – and non–significant linear 
correlations between these variables and the number of tests. We 
may thus anticipate two main dimensions discriminating countries: 
one concerning COVID–19 prevalence and another COVID–19 
diagnostic. 
Table 2 Linear correlation matrix 
Cases per 100.000 
until 02 May 2020
Deaths per 
100.000 until  
02 May 2020
Active Cases per 
100.000 until  
04 May 2020
Serious Critical 
per 100.000 until  
04 May 2020
Tests per 
100.000 until  
04 May 2020
Cases per 100.000 1.0000 0.8392 0.7257 0.7100 0.2687
Deaths per 100.000 0.8392 1.0000 0.7985 0.8712 0.0457
Active Cases per 100.000 0.7257 0.7985 1.0000 0.7060 0.0859
Serious Critical per 100.000 0.7100 0.8712 0.7060 1.0000 –0.0606
Tests per 100.000 0.2687 0.0457 0.0859 –0.0606 1.0000
In a third step a Principal Components Analysis (PCA) was applied 
to identify a small number of latent variables (principal components) 
likely to explain a significant part of the total variability of the data. 
Principal components are latent variables that restore the main part of 
the initial variability of the data in descending order and exhibit the 
property of being uncorrelated variables. Therefore, the new matrix 
constructed by this methodology can provide an interpretation of the 
data in a reduced dimension space, minimizing the overall loss of 
variability of the initial data. 
In the current situation the mean and variance of the epidemiologic 
variables are expressed in quite different orders of magnitude, so PCA 
was based on the correlation matrix. This means that the total variance 
of the standardized variables is equal to 5, the number of variables. 
The PCA outputs (Table 3) show that the variance of the first principal 
component is 𝜆1= 3.3, which means that first principal axis of inertia 
accounts for 66.8% of the total inertia. On the other hand, the second 
principal component has a variance of 𝜆2= 1.1 and therefore the 
second principal axis explains 21.2% of the total inertia. 
These two first principal axes of inertia thus explain 88% of the 
total inertia and hence we consider relatively irrelevant to retain an 
additional third axis. The examination of the factor loading matrix 
(Table 4) is crucial for the interpretation of the two retained factors – 
this Table describes the linear correlation coefficients between each of 
the principal components and the variables being studied. 
From Table 4 we may conclude that the first factor is a “size 
factor” positively correlated with all variables. This first axis explains 
the degree of COVID–19 prevalence across countries, opposing a set 
of countries where the pandemic had a very low or low prevalence on 
May 2 to another group of countries were the number of cases, critical 
cases, death and active cases knew a significant growth along March 
and April (Figure 2). 
In addition, the second principal axis is essentially related to 
the behavior of countries in what concerns the number of tests per 
100,000 inhabitants, opposing countries where such number was 
above the mean value, to other countries with lower tests numbers. 
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Table 4 also allows us to represent the epidemiological variables 
on the first principal plan, in the so–called “correlations circle” (Figure 
3), where the coordinates of each epidemiological variable relative 
to components 1 and 2 are simply the linear correlation coefficients 
between those variables and the two first principal components. In fact, 
all the variables represented here satisfy the condition: 𝑟2 (variable, 
F1) + 𝑟2 (variable, F2) ≤ 1, where the first member of this inequality 
corresponds to the part of the variance of each variable under study 
explained by the first two factors. 
Table 3 Principal Components Analysis (PCA): Eigenvalues
Number Eigenvalue Percent Cum Percent
1 3.3411 66.822 20 40 60 80 66.822
2 1.0616 21.231 20 40 60 80 88.053
3 0.2941 5.883 20 40 60 80 93.936
4 0.2163 4.325 20 40 60 80 98.261
5 0.0869 1.739 20 40 60 80 100.000
Table 4 Principal Components Analysis (PCA): loadings matrix
Prin1 Prin2
Cases per 100.000 until 02 May 2020 0.90486 0.19721
Deaths per 100.000 until 02 May 2020 0.96123 –0.08806
Active Cases per 100.000 until 04 May 2020 0.88312 –0.02501
Serious Critical per 100.000 until 04 May 2020 0.89503 –0.22480
Tests per 100.000 until 04 May 2020 0.13190 0.98171
Figure 2  Principal Components Analysis (PCA): Representation of countries on the first principal plan.
Considering our initial aim to characterize statistically the 
COVID–19 prevalence on May, 2, we used the factorial output 
explained by the two first factors for the construction of the Euclidean 
distance matrix between any pair of countries. We applied an ascending 
hierarchical cluster analysis to this matrix 𝐷31x31 (Figure 4), taking the 
Ward method as aggregation criteria at each iteration of the method. 
The dendogram suggested a partition of at least four clusters. 
This partition was then validated, using K–means non–hierarchical 
cluster analysis. The results of k–means partitions are suboptimal and 
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Figure 3 Principal Components Analysis (PCA): Correlation circle.
The first cluster includes the set of 6 countries with a higher total 
number of cases until May, 2, a mean value of about 376 cases per 
100,000 inhabitants (from a minimum of 247 to a maximum of 461). 
The maximum mean value of deaths also occurs in this cluster (about 
37 per 100,000 inhabitants) and the number of tests was the second 
best among the obtained clusters. 
The second cluster, with 4 countries, presents a smaller mean value 
of total cases (about 226 per 100,000 inhabitants) and a similar mean 
of deaths and active cases. However, in cluster 2 the serious critical 
cases were 50% higher than cluster 1 and the number of tests was less 
than half compared with cluster 1. 
Finally, the two other clusters, with 12 and 9 countries, presented 
a quite smaller number of total cases (a mean of 116 and 55 cases 
per 100,000 inhabitants, respectively for clusters 3 and 4), the main 
difference between them being related to the number of tests. Cluster 
3 displays a mean of 4,123 tests per 100,000 inhabitants and cluster 4 
just 1,155 tests. This significant difference could be explained by the 
low COVID–19 prevalence in the countries of cluster 4. 
A statistical rank analysis was then applied, described in Table 6. 
Considering the relative asymmetry of most of variables under study, 
we completed our analysis using a robust approach not conditioned by 
biased estimates of mean. From Table 6 it is clear the main difference 
between clusters 1 and 2 concerns the different priority given to the 
number of performed tests per 100,000 inhabitants. 
The two other clusters describe quite well the rank of countries in 
what concerns the four epidemiologic variables. Within cluster 3 there 
are two sub–groups explained again by the number of tests elaborated 
by respective countries. 
Finally, taking the EU countries of clusters 1 and 2, we analyzed 
eight non–pharmaceutical interventions taken by decision–makers:15,19
1. Stay home (enforced) 
2. Stay home (General Recommendation) 
3. Stay home, Risk Groups 
4. Closure secondary and Higher Schools 
5. Closure Primary Schools 
6. Closure Educational Care 
7. Closure Public Services 
8. Mass Gathering cancelations 
conditioned to the initial choice of number of clusters, here 4 clusters. 
The final solution will be local optima for the within–group variability 
(maximizing group homogeneity) and maximizing the between–group 
separability. The factorial plan 1–2 identifies the cluster partition. 
Table 5 characterizes each cluster through the “gravity center” of the 
respective countries. 
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Figure 4 Ascending Hierarchical Cluster Analysis – Dendrogram.
Clusters 1 and 2 included nine countries where the effects of the 
pandemic took a more worrying proportion in terms of health but 
also in economic and social terms. Table 7 indicates the measures 
implemented in each of the nine countries, as well as the date on 
which they were undertaken, concerning the period between February 
25 and April 25. 
Five main results may be observed from Table 7: 
• Sweden’s strategy towards COVID–19 was quite different from that 
of the other countries: just “Stay home – Risk Groups”, “Closure of 
Secondary and Higher Schools” and “Mass Gathering cancelations” 
were considered and implemented later than other countries;
•The Belgian and French strategies did not recommend staying at 
home, even for groups at risk; 
• The Italian strategy did not recommend staying home at an early 
stage of the pandemic and only later was decided as an enforced 
measure; 
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Figure 5 Principal Components Analysis (PCA): Representation of each cluster on the first factorial principal plan.
Table 5  Characterization of each cluster of countries
Cluster Partition
CL1 CL2 CL3 CL4
Cases per 100.000 until 02 May 2020
Mean 376,13 225,87 116,06 54,76
Standard Deviation 79,31 31,17 54,59 42,00
Minimum 246,56 194,34 45,16 22,61
Maximum 460,61 266,89 194,99 148,68
Valid N 6 4 12 9
Median 388,53 221,13 112,41 34,51
Percentile 25 343,25 202,84 70,71 25,76
Percentile 75 429,27 248,91 168,08 64,53
Deaths per 100.000 until 02 May 2020
Mean 36,66 33,13 3,71 2,38
Standard Deviation 22,57 7,15 2,59 1,41
Minimum 9,79 26,05 ,83 ,42
Maximum 67,44 41,38 7,93 3,96
Valid N 6 4 12 9
Median 36,39 32,56 3,19 1,83
Percentile 25 16,84 27,22 1,65 1,31
Percentile 75 53,13 39,04 5,58 3,82
• United Kingdom implemented all measures, but at a later stage in 
comparison with the other countries; 
• The “Mass Gathering cancelations” measure was implemented at 
an early stage of COVID–19 in Ireland, France, Portugal and Italy. 
In contrast, the UK only implemented this measure a month later.
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Cluster Partition
CL1 CL2 CL3 CL4
Active Cases per 100.000 until 04 May 2020
Mean 163,72 185,79 50,77 26,04
Standard Deviation 77,48 47,50 38,25 18,05
Minimum 35,19 138,67 15,92 10,37
Maximum 262,34 242,91 144,10 68,07
Valid N 6 4 12 9
Median 158,96 180,79 35,71 21,03
Percentile 25 145,61 147,30 26,98 13,68
Percentile 75 221,26 224,29 60,10 28,76
Serious Critical per 100.000 until                    
04 May 2020
Mean 2,99 4,07 ,84 ,68
Standard Deviation 1,83 1,32 ,59 ,50
Minimum 1,39 2,34 ,21 ,13
Maximum 5,73 5,52 2,35 1,68
Valid N 6 4 12 9
Median 2,18 4,22 ,70 ,53
Percentile 25 1,66 3,15 ,48 ,37
Percentile 75 4,82 4,99 1,12 ,89
Tests per 100.000 until 04 May 2020
Mean 3801,16 1531,90 4122,54 1155,01
Standard Deviation 401,40 334,57 1420,13 438,03
Minimum 3320,01 1173,50 2461,47 699,65
Maximum 4376,68 1942,56 7487,44 1875,66
Valid N 6 4 12 9
Median 3742,30 1505,77 3826,23 1010,58
Percentile 25 3489,79 1271,30 3112,90 859,45
Percentile 75 4135,92 1792,50 4857,00 1422,67
Table 6 Statistical rank analysis by countries and associated clusters
Cluster Countries/VAR
Cases       
Per 100 000 
Death             
Per 100 000
Active cases 
per 100 000
Serious critical  
per 100 000
Tests        
per 100 000
1
CHE 4 3 2 3 3
PRT 4 3 4 3 4
IRL 4 4 4 3 3
ITA 4 4 4 4 3
ESP 4 4 4 4 3
BELG 4 4 4 4 3
2
UK 4 4 4 3 2
NL 3 4 4 4 1
FR 3 4 3 4 2
SE 3 4 4 4 1
Table Continued
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Table Continued
Cluster Countries/VAR
Cases       
Per 100 000 
Death             
Per 100 000
Active cases 
per 100 000
Serious critical  
per 100 000
Tests        
per 100 000
3
CZE 2 2 2 2 2
SVN 2 2 3 2 2
LVA 1 1 2 1 3
AUT 3 3 1 3 3
NOR 2 2 3 2 3
DEU 3 3 2 3 2
DNK 3 3 2 2 4
EST 2 2 3 1 4
ISR 3 2 3 2 4
CYP 2 1 3 3 4
LTU 1 1 2 2 4
MLT 2 1 1 1 4
4
HVR 1 2 1 1 1
POL 1 2 1 1 1
GRC 1 1 1 1 1
BGR 1 1 1 2 1
HUN 1 2 1 2 1
ROU 2 2 2 3 1
FIN 2 2 2 2 2
SVK 1 1 1 1 2
TUR 3 2 3 3 2
1: Below first quartile
2: Between first quartile and median
3: Between median and 3.º quartile
4: Above 4.º quartile
Table 7 List of non–pharmaceutical governmental measures against COVID–19 (until May, 2)
Recomend 
Group
Risk 
Group
Closure 
Second 
Higher
Closure 
Second 
Higher
Closure Closure Mass Gattering Cancellations
PRT NO at 17/3 at 10/3 at 12/3 at 12/3 at 12/3 at 12/3 at 04/3
IRL at 26/3 from 13/3 to 
25/3
at 13/3 at 13/3 at 13/3 at 13/3 at 13/3 at 25/2
ITA at 12/3 NO at 04/3 at 04/3 at 04/3 at 04/3 at 12/3 at 04/3
ESP at 15/3 from 08/3 to 
14/3
at 12/3 at 12/3 at 12/3 at 12/3 at 14/3 at 14/3
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Recomend 
Group
Risk 
Group
Closure 
Second 
Higher
Closure 
Second 
Higher
Closure Closure Mass Gattering Cancellations
BELL at 20/3 NO NO at 13/3 at 13/3 NO at 13/3 at 10/3
UK at 24/3 from 17/3 to 
23/3
at 17/3 at 22/3 at 22/3 at 22/3 at 17/3 at 24/3
NL at 25/3 from 17/3 to 
22/3
at 13/3 at 12/3 at 17/3 at 17/3 at 12/3 at 12/3
FR at 19/3 NO NO
 
at 17/3
at 17/3 at 17/3 at 17/3 at 28/2
 
SE NO NO
 
at 20/3
 
at 18/3
NO NO NO
 
at 12/3
Table Continued
Discussion
The objective of this cross–sectional study was to describe the 
COVID–19 prevalence at the beginning of May 2020, in European 
Union Countries also belonging other European OECD countries.
The epidemiological variables under study were: total number 
of COVID–19 cases, total number of deaths, total number of active 
cases, total number of critical serious cases and total number of tests. 
The first four variables were positively correlated and uncorrelated 
with the number of tests. In order to obtain a typology of countries that 
explained their COVID–19 prevalence, four clusters were chosen. 
Clusters 1 and 2 include countries where the epidemic has reached a 
higher impact than the global average in the first four variables under 
study. However, among these nine countries, Switzerland and Portugal 
presented better results in what concerned the numbers of deaths and 
of critical serious cases per 100,000 inhabitants. We also emphasize 
the fact that clusters 1 and 2 are distinguished by the number of tests 
performed. In fact, the number of tests in cluster 2 was significantly 
smaller, especially in Sweden and the Netherlands with values below 
the global first quartile. For the cluster 1, all the countries presented a 
number of tests above the global median with emphasis on Portugal, 
where this value was above the third global quartile. The analysis of 
the third cluster revealed a lower COVID–19 prevalence, although 
seven of the twelve countries in this cluster had at least one of the 
four epidemiologic variables with values above the global median. 
Cluster 3 featured six countries where the number of tests exceeded 
the third global quartile. Cluster 4 included a set of nine countries with 
heterogeneous geographies where the COVID–19 prevalence was 
particularly low, generally below the global median or even below 
the first quartile. Turkey was an exception with the number of cases 
namely active cases per 100,000 inhabitants and the number of serious 
critical cases above the global median. Due to the asymmetry of the 
empirical distribution of some of the epidemiological variables, and 
the consequent bias in the respective means, we validated the previous 
results using the statistical rank analysis.
Regarding our second aim, we established some associations 
between the measures implemented by the Governments in the first 
phase of the pandemic and the COVID–19 prevalence data over the 
period until early May 2020.
This investigation covered just EU countries belonging to the 
two first clusters, the countries hardest hit by COVID–19. The eight 
selected measures preventing the degree of contamination of this viral 
epidemic were: stay at home (enforced), stay home recommendation, 
stay home for risk group, closure of secondary and higher schools, 
closure of primary schools, closure of educational care day, closure of 
public services and mass gathering cancellations. 
We have associated to each measure three modalities: not 
implemented, implemented at an early date (before March 17, 2020), 
and implemented at a later date (on or after March 17, 2020). Global 
behaviors of the EU countries of clusters 1 and 2 were represented by 
a disjunctive table. Our approach generated a cluster analysis which 
reproduced the two classes of countries previously obtained, with the 
exception of Sweden, which constituted an isolated group in views of 
this country’s completely different strategy in combating COVID–19.
Timings of the implementation of non–pharmaceutical 
interventions may thus have had an impact of the structure of the 
obtained country clusters. This impact may be assessed in terms 
of prevalence indicators, but also in economic terms, and both are 
relevant in the future to identify the best approaches.19–21 
Future studies will further analyse the following cycles, as less 
restrictive measures will be undertaken regarding the mobility of 
populations, economic activity and more advanced deconfinement 
phases.
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Conclusions
In the present paper four classes were identified to obtain a 
typology of countries that would describe their COVID–19 prevalence. 
Essentially, we identify a set of ten countries where such prevalence 
generates a real concern, testing throughout the period under study 
the capacity of health services. Fortunately, in same countries (like 
Switzerland and Portugal) the number of serious critical cases did not 
exceed the health logistical available, although in Portugal patients’ 
access to non–COVID–19 health services may have been hindered.22 
There is some evidence that non–pharmaceutical measures taken from 
February, 25 until April, 25 had the desire impact of controlling the 
epidemic within reasonable limits, but we know that the key aims of 
these measures will be to reduce the effective reproduction number 
Rt, a quite crucial epidemiological quantity representing the average 
number of infection generated at time t, by each injected case over the 
course of their infections.
However, data referenced of our present study do not access some 
potentially relevant equity issues, like the impact of Swedish strategy 
in terms of COVID–19 prevalence over some risk level groups like 
the elderly.
Our next studies will try to identify which interventions are 
necessary to maintain control over epidemiological variables, while 
also manage the trade–off regarding their impact on economic, 
financial and social costs.
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